Navigation Links
Bioness Inc Announces Availability of L300 Plus System
Date:8/29/2011

VALENCIA, Calif., Aug. 29, 2011 /PRNewswire/ -- Bioness Inc., today announced the commercial release of its NESS L300® Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300® Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.

The L300 Plus is intended for people living with neurological conditions resulting from stroke, multiple sclerosis, traumatic brain injury and spinal cord injury. The L300 Plus also helps to facilitate muscle re-education, prevent muscle atrophy, increase range of motion and increase local blood flow.

Sheltering Arms Physical Rehabilitation Centers located in Richmond, Va. is the first rehabilitation center in the country to offer the L300 Plus. According to James E. Sok, President and CEO, "The L300 Plus is a welcomed addition to our iWalk program which empowers our patients by offering a wide-range of technology-based therapy solutions. We are excited to offer leading rehab technologies in combination with our highly trained therapists to help restore function in our patients as they reintegrate back into the community."  

"For individuals living with central nervous system disorders, lack of mobility can be a challenging and life-altering issue," said Todd Cushman, Senior Vice President of Global Sales, Business Development and Marketing for Bioness. "With the L300 Plus, we aim to provide the more than 150,000 physical therapists and 3,200 neurorehabilitation clinics in the United States another option for helping neurological patients with gait disorders."

The L300 Plus is now commercially available to neurorehabilitation hospitals and centers around the country, and to consumers for home use.

For more information about the Bioness L300 Plus System and other Bioness devices, please call 800.211.9136 Option 2, or visit www.bioness.com.

About Bioness Inc.

Bioness provides neuromodulation technologies that help improve lives and restore function for those living with neurological deficits and peripheral pain. The Company designs and markets innovative neuromodulation products that help individuals with central nervous system disorders such as stroke, multiple sclerosis, spinal cord injury and traumatic brain injury regain movement in affected limbs. The NESS L300® Foot Drop System, NESS H200® Hand Rehabilitation System, and NESS L300® Plus System are cleared for use by the Food and Drug Administration and may help patients achieve new levels of physical independence and productivity.

Individual results vary. Consult with a qualified physician to find out if these products are right for you. Additional information about Bioness can be found at www.bioness.com.

NESS®, NESS H200®, NESS L300®, NESS L300® Plus, Bioness® are trademarks of Bioness Inc. | www.bioness.com | Rx Only

Media Contact:

Wendy Ryan/Genevieve Gadenne
Schwartz Communications
781-684-0770
bioness@schwartzcomm.com


'/>"/>
SOURCE Bioness Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance of Its NESS L300 Plus System
2. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
3. Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility
4. Masters Pharmaceutical, Inc. Announces DEA Registration for New Distribution Center
5. Life Extension® Announces Recruitment for Alzheimers Clinical Trial in South Florida
6. PDI Announces Renewal of Engagement for 7th Consecutive Season
7. Nutrastar Announces Adoption of Share Repurchase Program
8. ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies
9. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock
10. ChemOutsourcing Announces the 62 Exhibitors to Present API & New Chemical Technologies at September 12-15, 2011 Show in NJ
11. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):